Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.52 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 7/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009831 | 1.00 | TGFBR1 (0.52) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL6253538 | 0.89 | ACE (0.49) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL2633846 | 0.87 | ACE (0.47) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL28806122 | 0.85 | OR51E2 (0.44) | TGFBR1OR51E2MMEACEFOLH1 | |
| SCHEMBL8491732 | 0.85 | OR51E2 (0.44) | TGFBR1OR51E2MMEACEFOLH1 | |
| SCHEMBL4363673 | 0.85 | ACE (0.58) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL321602 | 0.85 | ACE (0.58) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL29837094 | 0.85 | OR51E2 (0.44) | TGFBR1OR51E2MMEACEFOLH1 | |
| SCHEMBL8216927 | 0.85 | ACE (0.58) | TGFBR1OR51E2MMEACECA2 | |
| SCHEMBL8491734 | 0.85 | OR51E2 (0.44) | TGFBR1OR51E2MMEACEFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0926955-A4 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-5998362-A | OLIGOPEPTIDES, HAVING AMINO ACID SEQUENCES THAT ARE SELECTIVELY PROTEOLYTICALLY CLEAVED BY FREE PROSTATE SPECIFIC ANTIGEN (PSA), HYDROPHILIC OLIGOPEPTIDE BLOCKING GROUPS | MERCK & CO., INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0926955-A1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | Merck & Co., Inc. (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998010651-A1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 1998-03-19 | — | — | WO | disclosed |